Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Camilla Stapnes, Bjørn Tore Gjertsen, Håkon Reikvam & Øystein Bruserud. (2009) Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs 18:4, pages 433-455.
Read now
Read now
Åsa Rangert Derolf, Elisabet Björklund, Joanna Mazur, Magnus Björkholm & Anna Porwit. (2008) Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia. Leukemia & Lymphoma 49:7, pages 1279-1291.
Read now
Read now
Maria Kraj, Ryszard Pogłód, Joanna Kopeć-szlęzak, Urszula Sokołowska, Jolanta Woźniak & Barbara Kruk. (2004) C-kit Receptor (CD117) Expression on Plasma Cells in Monoclonal Gammopathies. Leukemia & Lymphoma 45:11, pages 2281-2289.
Read now
Read now
Peter Jacobs & Lucille Wood. (2002) Myelodysplasia and the Acute Myeloid Leukaemias. Hematology 7:6, pages 325-338.
Read now
Read now
Articles from other publishers (46)
Aref Al‐Kali, Raoul Tibes, Pamela Atherton, Jeanne Palmer, Hassan B. Alkhateeb, Mrinal Patnaik, Kebede Begna, Naseema Gangat, Shahrukh Hashmi, Rong He & Mark Litzow. (2023)
A phase
II
study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (
TAsigna
) (
DATA
) in patients newly diagnosed with acute myeloid leukemia with
KIT
expression
. American Journal of Hematology 98:3, pages 472-480.
Crossref
Crossref
Renier Myburgh, Jonathan D. Kiefer, Norman F. Russkamp, Chiara F. Magnani, Nicolás Nuñez, Alexander Simonis, Surema Pfister, C. Matthias Wilk, Donal McHugh, Juliane Friemel, Antonia M. Müller, Burkhard Becher, Christian Münz, Maries van den Broek, Dario Neri & Markus G. Manz. (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34:10, pages 2688-2703.
Crossref
Crossref
Marta Chisini, Caterina Stefanizzi, Teresa Ceglie, Sara Raponi, Federico Vozella, Gioia Colafigli, Adriano Salaroli, Mariella D'Angiò, Marco Mancini, Daniela Diverio, Massimo Breccia, Francesca Mancini, Clara Minotti, Silvia Trisolini, Saveria Capria, Anna Maria Testi, Anna Guarini, Roberto Latagliata, Maria Stefania De Propris & Robin Foà. (2017) Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. Hematological Oncology 35:4, pages 804-809.
Crossref
Crossref
Alan Pomerantz, Sergio Rodríguez-Rodríguez, Roberta Demichelis-Gómez, Georgina Barrera-Lumbreras, Olga V. Barrales-Benítez, María José Díaz-Huízar, Monica Goldberg-Murow, Xavier López-Karpovitch & Álvaro Aguayo. (2017) Importance of CD117 in the Assignation of a Myeloid Lineage in Acute Leukemias. Archives of Medical Research 48:2, pages 212-215.
Crossref
Crossref
John Adams Fischer, Stefano Rossetti, Arani Datta, Kevin Hasegawa Eng, Alessandro Beghini & Nicoletta Sacchi. (2015) miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Molecular Cancer 14:1.
Crossref
Crossref
Maria Concepcion García-Dabrio, Montserrat HoyosSalut BrunetMar TormoJosep-Maria RiberaJordi EsteveDavid GallardoRafael F. DuarteMaria Paz Queipo de LlanoJoan BargayJosep M. Martí-TutusausInmaculada HerasAntoni GarciaOlga Salamero, Anna Aventin, Quentin LecrevisseAlberto OrfaoJorge SierraJosep F. Nomdedéu. (2015) Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. American Journal of Clinical Pathology 144:3, pages 484-492.
Crossref
Crossref
Øystein Bruserud, Håkon Reikvam, Hanne Fredly, Jørn Skavland, Karen-Marie Hagen, Tuyen Thy van Hoang, Annette K. Brenner, Amir Kadi, Audrey Astori, Bjørn Tore Gjertsen & Frederic Pendino. (2014) Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget 6:5, pages 2794-2811.
Crossref
Crossref
Abbas Ahmadi, Ali-Akbar Poorfathollah, Mahnaz Aghaiipour, Mansour Rezaei, Mahin Nikoo-ghoftar, Mohammad Abdi, Alireza Gharib & Amir Amini. (2014) Diagnostic value of CD117 in differential diagnosis of acute leukemias. Tumor Biology 35:7, pages 6763-6768.
Crossref
Crossref
Beatriz de Melo Maia, André Mourão Lavorato-Rocha, Iara Sant’Ana Rodrigues, Glauco Baiocchi, Flávia Munhoz Cestari, Monica Maria Stiepcich, Ludmila Thomé Domingues Chinen, Kátia C Carvalho, Fernando Augusto Soares & Rafael Malagoli Rocha. (2012) Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside. Journal of Translational Medicine 10:1.
Crossref
Crossref
Angela Ferrari, Elena Bussaglia, Josep Úbeda, Luca Facchini, Anna Aventin, Jorge Sierra & Josep F. Nomdedéu. (2011) Immunophenotype distinction between acute promyelocytic leukaemia and CD15− CD34− HLA‐DR− acute myeloid leukaemia with nucleophosmin mutations. Hematological Oncology 30:3, pages 109-114.
Crossref
Crossref
Marianne Hutchings Hoffmann, Tobias Wirenfeldt Klausen, Martin Boegsted, Steffen Falgreen Larsen, Alexander Schmitz, Eva Birgitte Leinoe, Kjeld Schmiegelow, Henrik Hasle, Olav Jonas Bergmann, Suzette Sorensen, Mette Nyegaard, Karen Dybkær & Hans Erik Johnsen. (2012) Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate‐risk acute myeloid leukemia. Cytometry Part B: Clinical Cytometry 82B:3, pages 123-131.
Crossref
Crossref
Stefan Faderl, Carlos Bueso-Ramos, Zhiming Liu, Ashutosh Pal, William Bornmann, Diana V. Ciurea, David Harris, Inbal Hazan-Halevy, Hagop M. Kantarjian & Zeev Estrov. (2010) Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Investigational New Drugs 29:5, pages 1094-1097.
Crossref
Crossref
A. V. Rulina, P. V. Spirin & V. S. Prassolov. (2011) Activated leukemic oncogenes AML1-ETO and c-kit: Role in development of acute myeloid leukemia and current approaches for their inhibition. Biochemistry (Moscow) 75:13, pages 1650-1666.
Crossref
Crossref
Eric Schafer & Donald Small. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
56
76
.
Rebecca D. Chernock, Arie Perry, John D. Pfeifer, Joseph A. Holden & James S. LewisJrJr. (2009) Receptor tyrosine kinases in sinonasal undifferentiated carcinomas—Evaluation for EGFR, c‐KIT, and HER2/neu expression. Head & Neck 31:7, pages 919-927.
Crossref
Crossref
T. M. MuraliCorban G. Rivera. (2008) Network Legos: Building Blocks of Cellular Wiring Diagrams. Journal of Computational Biology 15:7, pages 829-844.
Crossref
Crossref
Claudia Scholl, D. Gary Gilliland & Stefan Fröhling. (2008) Deregulation of Signaling Pathways in Acute Myeloid Leukemia. Seminars in Oncology 35:4, pages 336-345.
Crossref
Crossref
Anjali S. Advani, Cristina Rodriguez, Tao Jin, Rony Abou Jawde, Wael Saber, Rachid Baz, Matt Kalaycio, Ronald Sobecks, Mikkael Sekeres, Barbara Tripp & Eric Hsi. (2008) Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leukemia Research 32:6, pages 913-918.
Crossref
Crossref
Florian Heidel, Jorge Cortes, Frank G. Rücker, Walter Aulitzky, Laurie Letvak, Thomas Kindler, Christoph Huber, Hartmut Döhner, Hagop Kantarjian & Thomas Fischer. (2007) Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib. Cancer 109:5, pages 907-914.
Crossref
Crossref
Martin Schwonzen, Volker Diehl, Mario Dellanna & Peter Staib. (2007) Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis. Leukemia Research 31:1, pages 113-116.
Crossref
Crossref
T. M. Murali & Corban G. Rivera. 2007. Research in Computational Molecular Biology. Research in Computational Molecular Biology
47
61
.
Anjali S. Advani. (2006) Targeting the c-kit receptor in the treatment of acute myelogenous leukemia. Current Hematologic Malignancy Reports 1:2, pages 101-107.
Crossref
Crossref
C. Lu & H.T. Hassan. (2006) Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Leukemia Research 30:3, pages 296-302.
Crossref
Crossref
Markku Miettinen & Jerzy Lasota. (2005) KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Applied Immunohistochemistry & Molecular Morphology 13:3, pages 205-220.
Crossref
Crossref
Johan Lennartsson, Tanya Jelacic, Diana Linnekin & R. Shivakrupa. (2009) Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. STEM CELLS 23:1, pages 16-43.
Crossref
Crossref
E. Paietta, O. Goloubeva, D. Neuberg, J. M. Bennett, R. Gallagher, J. Racevskis, G. Dewald, P. H. Wiernik & M. S. Tallman. (2004) A surrogate marker profile for PML/RAR? expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry 59B:1, pages 1-9.
Crossref
Crossref
Michaela Graf, Karin Hecht, Susanne Reif, Renate Pelka-Fleischer, Karin Pfister & Helga Schmetzer. (2004) Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. European Journal of Haematology 72:2, pages 89-106.
Crossref
Crossref
Matthias Krams, Reza Parwaresch, Bence Sipos, Klaus Heidorn, Dieter Harms & Pierre Rudolph. (2004) Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 23:2, pages 588-595.
Crossref
Crossref
Sophie Song & Faramarz Naeim. 2004. Cancer Diagnostics. Cancer Diagnostics
199
232
.
Richard Schabath, Richard Ratei & Wolf-Dieter Ludwig. (2003) The prognostic significance of antigen expression in leukaemia. Best Practice & Research Clinical Haematology 16:4, pages 613-628.
Crossref
Crossref
Elisabeth Paietta. (2003) Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Practice & Research Clinical Haematology 16:3, pages 369-385.
Crossref
Crossref
Jorge Cortes, Francis Giles, Susan O'Brien, Deborah Thomas, Maher Albitar, Mary Beth Rios, Moshe Talpaz, Guillermo Garcia‐Manero, Stefan Faderl, Laurie Letvak, August Salvado & Hagop Kantarjian. (2003) Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97:11, pages 2760-2766.
Crossref
Crossref
R. Repp, U. Schaekel, G. Helm, C. Thiede, S. Soucek, U. Pascheberg, H. Wandt, W. Aulitzky, H. Bodenstein, R. Sonnen, H. Link, G. Ehninger & M. Gramatzki. (2003) Immunophenotyping is an independent factor for risk stratification in AML. Cytometry 53B:1, pages 11-19.
Crossref
Crossref
O Hrušák & A Porwit-MacDonald. (2002) Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 16:7, pages 1233-1258.
Crossref
Crossref
Ikuo MurohashiKatsuhiko YoshidaKuniya KishimotoTakashi TakahashiDaisuke WakaoItsuro JinnaiFumiharu YagasakiNobutaka KawaiToshiya SuzukiAkira MatsudaKunitake HirashimaMasami Bessho. (2002) Differential Response to Stem Cell Factor and Flt3 Ligand by the FAB Subtype in Acute Myeloid Leukemia Clonogenic Cells. Journal of Interferon & Cytokine Research 22:3, pages 335-341.
Crossref
Crossref
Cristina Mecucci, Roberto Rosati & Roberta La Starza. (2002)
G
ENETIC
P
ROFILE
OF
A
CUTE
M
YELOID
L
EUKEMIA
. Reviews in Clinical and Experimental Hematology 6:1, pages 3-25.
Crossref
Crossref
Christine P. Hans, William G. Finn, Timothy P. Singleton, Bertram Schnitzer & Charles W. Ross. (2002) Usefulness of Anti-CD117 in the Flow Cytometric Analysis of Acute Leukemia. American Journal of Clinical Pathology 117:2, pages 301-305.
Crossref
Crossref
Farhad Ravandi, Moshe Talpaz, Hagop Kantarjian & Zeev Estrov. (2002) CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY. British Journal of Haematology 116:1, pages 57-77.
Crossref
Crossref
Francisco José Ortuño Giner & Alberto Orfao. (2002) Aplicación de la citometría de flujo al diagnóstico y seguimiento inmunofenotípico de las leucemias agudas. Medicina Clínica 118:11, pages 423-436.
Crossref
Crossref
KU Birkenkamp, M Geugien, HH Lemmink, W Kruijer & E Vellenga. (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:12, pages 1923-1931.
Crossref
Crossref
Bob L?wenberg. (2001) Prognostic factors in acute myeloid leukaemia. Best Practice & Research Clinical Haematology 14:1, pages 65-75.
Crossref
Crossref
T. Benter, R. Ratei & W.-D. Ludwig. (2001) Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien. LaboratoriumsMedizin 25:11-12, pages 512-532.
Crossref
Crossref
C Brendel & A Neubauer. (2000) Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia 14:10, pages 1711-1717.
Crossref
Crossref
Øystein Bruserud, Brynjar Foss, Jenny Foss Abrahamsen, Bjørn Tore Gjertsen & Peter Ernst. (2000) Autologous Stem Cell Transplantation As Post-Remission Therapy in Adult Acute Myelogenous Leukemia: Does Platelet Contamination of Peripheral Blood Mobilized Stem Cell Grafts Influence the Risk of Leukemia Relapse?. Journal of Hematotherapy & Stem Cell Research 9:4, pages 433-443.
Crossref
Crossref
Grace M. Cuenco, Giuseppina Nucifora & Ruibao Ren. (2000) Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. Proceedings of the National Academy of Sciences 97:4, pages 1760-1765.
Crossref
Crossref
Alessandro Beghini, Paolo Peterlongo, Carla B. Ripamonti, Lidia Larizza, Roberto Cairoli, Enrica Morra & Cristina Mecucci. (2000) C-kit mutations in core binding factor leukemias. Blood 95:2, pages 726-728.
Crossref
Crossref